Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Ortho-McNeil agrees to acquire Cygnus' drug delivery technology platform and most of its products, including the nicotine patch Nicotrol, two hormone replacement transdermal products and the contraceptive patch Edra. McNeil Consumer Healthcare already markets Nicotrol in the U.S. Cygnus will receive $20 mil. at closing and the remaining $55 mil. will be contingent on the attainment of technical, regulatory and commercialization milestones for Edra. Ortho-McNeil expects to file an NDA for Edra in January. Cygnus plans to focus on its GlucoWatch device, which monitors glucose levels and is up for an FDA advisory committee review Dec. 6



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts